Bayer Pharma Lab
+ 351 21 446 9454
Gabriela M Silva is a Scientist at the Animal Cell Technology Unit of IBET – Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Gabriela Silva obtained her MSc in Biology, specialization in Microbiology, from the Moscow State University, Russia, and a holds a PhD in Biology from the Instituto de Tecnologia Quíimica Biológica, Universidade Nova de Lisboa, Portugal. She became a post-doc in the laboratory of Dr. Miguel Soares at the Instituto Gulbenkian de Ciência in Portugal (2002-2008) where she worked in projectsaiming to identify the mechanisms via which heme oxygenase-1 affords cytoprotective and anti-inflammatory effects in endothelial cells, a process contributing to the potent protective effects of this protein in a variety of diseases. Still at this laboratory she identified that fully oxidized hemoglobin acts as a potent pro-inflammatory agonist in endothelial cells. Her growing interest in cancer research directed her second post-doc at the Unidade de Investigação de Patobiologia Molecular from the Instituto Português de Oncologia Francisco Gentil, Lisboa, Portugal (2009-2013). The projects where she worked at the laboratory of Dr. António Almeida involved the effects and molecular mechanisms of action of an HDAC inhibitor on hematologic malignancies, envisioning it´s therapeutic use. From 2013 to 2014, as a scientist at the Department of Molecular Oncology from the King Faisal Specialist Hospital and Research Center, Riyadh, King of Saudi Arabia, she conducted research in the laboratory of Dr. Abdelilah Aboussekhra on the mechanisms underlying p16 anti-oncogenic effects in osteosarcoma and stromal fibroblast transformation in breast cancer progression. Since October 2014, she has been working as a scientist at iBET, on projects in the fields of biopharmaceutical process development and oncology.